1. Home
  2. KOPN vs CRDF Comparison

KOPN vs CRDF Comparison

Compare KOPN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kopin Corporation

KOPN

Kopin Corporation

HOLD

Current Price

$2.73

Market Cap

396.8M

Sector

Technology

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.56

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOPN
CRDF
Founded
1984
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.8M
130.7M
IPO Year
2025
2012

Fundamental Metrics

Financial Performance
Metric
KOPN
CRDF
Price
$2.73
$1.56
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$4.25
$9.63
AVG Volume (30 Days)
3.1M
555.2K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
N/A
N/A
Revenue
$1,044,337.00
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
$40.97
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
49.61
52 Week Low
$0.79
$1.48
52 Week High
$4.16
$4.56

Technical Indicators

Market Signals
Indicator
KOPN
CRDF
Relative Strength Index (RSI) 63.58 34.21
Support Level $2.24 $1.51
Resistance Level $2.74 $1.68
Average True Range (ATR) 0.24 0.08
MACD 0.08 -0.01
Stochastic Oscillator 96.35 4.55

Price Performance

Historical Comparison
KOPN
CRDF

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: